Trump Proposes 200% Pharma Tariffs to Force Domestic Production

President Donald Trump proposed tariffs of up to 200% on pharmaceutical imports from China, India, and the European Union to reduce reliance on foreign markets and force domestic production. The administration is utilizing the International Emergency Economic Powers Act to implement the measures, though the legal authority is facing challenges with an appellate hearing scheduled for July 31.

In response, several major pharmaceutical companies announced massive investments in U.S. manufacturing. AstraZeneca and Roche each committed $50 billion, while Eli Lilly and Company announced $27 billion to build four new production mega sites focusing on injectables and active pharmaceutical ingredients. Additional investments include $12 billion from Merck and $2 billion from BioGen.

Despite these financial commitments, industry readiness remains a concern. Research from consultancy Sia indicates only one in seven pharmaceutical companies could shift production to the U.S. within three months. Executives cited regulatory uncertainty and a lack of preparedness as primary obstacles to a rapid transition.